Evolution and emergence of a new era of antiviral treatment for chronic hepatitis C infection

Teegan Lim; B. H. Tan; D J Mutimer

doi:10.1016/j.ijantimicag.2013.09.008

Evolution and emergence of a new era of antiviral treatment for chronic hepatitis C infection

Teegan Lim, B. H. Tan, D J Mutimer

Immunology and Immunotherapy

Research output: Contribution to journal › Article › peer-review

9 Citations (Scopus)

Abstract

Chronic hepatitis C virus (HCV) infection is a major public health burden associated with significant morbidity and mortality. The approval of telaprevir and boceprevir for use with interferon and ribavirin in chronic HCV infection significantly increased viral eradication but has been accompanied by increased adverse events and therefore inferior clinical tolerance. Newer classes of antiviral agents, such as directly acting antiviral and host-targeting agents, offer a combination of drugs without the need for interferon and can achieve better response rates with a shorter duration of treatment. This offers an exciting prospect in the new era of antiviral treatment for HCV infection.

Original language	English
Pages (from-to)	17-25
Number of pages	9
Journal	International Journal of Antimicrobial Agents
Volume	43
Issue number	1
Early online date	15 Oct 2013
DOIs	https://doi.org/10.1016/j.ijantimicag.2013.09.008
Publication status	Published - 1 Jan 2014

Keywords

Antiviral Agents
Drug Therapy, Combination
Hepatitis C, Chronic
Humans
Oligopeptides
Proline
Hepatitis C
Antiviral treatment
Directly acting antiviral

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ijantimicag.2013.09.008Licence: None: All rights reserved

https://doi.org/10.1016/j.ijantimicag.2013.09.008Licence: None: All rights reserved

Hepatic Steatosis and Insulin Resistance in Hepatitis C Infection
Lim, T.
Medical Research Council
1/10/12 → 1/01/17
Project: Research Councils

Cite this

@article{bf30a3b1257a4bbfa168054960e018da,

title = "Evolution and emergence of a new era of antiviral treatment for chronic hepatitis C infection",

abstract = "Chronic hepatitis C virus (HCV) infection is a major public health burden associated with significant morbidity and mortality. The approval of telaprevir and boceprevir for use with interferon and ribavirin in chronic HCV infection significantly increased viral eradication but has been accompanied by increased adverse events and therefore inferior clinical tolerance. Newer classes of antiviral agents, such as directly acting antiviral and host-targeting agents, offer a combination of drugs without the need for interferon and can achieve better response rates with a shorter duration of treatment. This offers an exciting prospect in the new era of antiviral treatment for HCV infection.",

keywords = "Antiviral Agents, Drug Therapy, Combination, Hepatitis C, Chronic, Humans, Oligopeptides, Proline, Hepatitis C, Antiviral treatment, Directly acting antiviral",

author = "Teegan Lim and Tan, {B. H.} and Mutimer, {D J}",

year = "2014",

month = jan,

day = "1",

doi = "10.1016/j.ijantimicag.2013.09.008",

language = "English",

volume = "43",

pages = "17--25",

journal = "International Journal of Antimicrobial Agents",

issn = "0924-8579",

publisher = "Elsevier",

number = "1",

}

TY - JOUR

T1 - Evolution and emergence of a new era of antiviral treatment for chronic hepatitis C infection

AU - Lim, Teegan

AU - Tan, B. H.

AU - Mutimer, D J

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Chronic hepatitis C virus (HCV) infection is a major public health burden associated with significant morbidity and mortality. The approval of telaprevir and boceprevir for use with interferon and ribavirin in chronic HCV infection significantly increased viral eradication but has been accompanied by increased adverse events and therefore inferior clinical tolerance. Newer classes of antiviral agents, such as directly acting antiviral and host-targeting agents, offer a combination of drugs without the need for interferon and can achieve better response rates with a shorter duration of treatment. This offers an exciting prospect in the new era of antiviral treatment for HCV infection.

AB - Chronic hepatitis C virus (HCV) infection is a major public health burden associated with significant morbidity and mortality. The approval of telaprevir and boceprevir for use with interferon and ribavirin in chronic HCV infection significantly increased viral eradication but has been accompanied by increased adverse events and therefore inferior clinical tolerance. Newer classes of antiviral agents, such as directly acting antiviral and host-targeting agents, offer a combination of drugs without the need for interferon and can achieve better response rates with a shorter duration of treatment. This offers an exciting prospect in the new era of antiviral treatment for HCV infection.

KW - Antiviral Agents

KW - Drug Therapy, Combination

KW - Hepatitis C, Chronic

KW - Humans

KW - Oligopeptides

KW - Proline

KW - Hepatitis C

KW - Antiviral treatment

KW - Directly acting antiviral

U2 - 10.1016/j.ijantimicag.2013.09.008

DO - 10.1016/j.ijantimicag.2013.09.008

M3 - Article

C2 - 24183752

SN - 0924-8579

VL - 43

SP - 17

EP - 25

JO - International Journal of Antimicrobial Agents

JF - International Journal of Antimicrobial Agents

IS - 1

ER -

Evolution and emergence of a new era of antiviral treatment for chronic hepatitis C infection

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Projects

Hepatic Steatosis and Insulin Resistance in Hepatitis C Infection

Cite this